Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
OECD data remains incomplete: Public sources often exclude non-retail drug use and post-hoc rebates, requiring methodological enhancements to estimate true total expenditure
A New Treatment modality for rheumatoid arthritis: combined Photothermal and photodynamic therapy using cu(7.2) S(4) nanoparticles, Adv Healthc Mater
The modern era of MS therapy reached primary progressive MS in 2018, with the approval of ocrelizumab
Additionally, extreme values in the dataset were removed when identified as outliers through Grubbs method
US$ 22.66
US$ 28.27
US$ 26.28
US$ 20.42
US$ 23.85
US$ 27.65
US$ 27.23
US$ 23.19
US$ 22.60
US$ 24.91
